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1. Introduction
“Woe to the child who tastes salty from a kiss on the brow, for he is cursed 
and soon must die,” describes European folklore and medical texts of middle ages 
a condition then unknown. It took several centuries for this condition to get its 
formal name from an American Pathologist Dr. Dorothy Anderson- cystic fibrosis 
[1]. While conducting an autopsy of a child apparently died of Celiac disease, she 
found ‘cystic fibrosis of the pancreas’ and her later research for over a decade defined 
the characteristics of the disease that involved pancreas, lungs and intestine [2]. 
Dr. Paul di Sant’Agnese in 1948 New York heatwave noticed a higher concentration 
of salt in the sweat of dehydrated children leading to the first, most reliable and 
yet ubiquitously used ‘sweat test’ for the CF [3]. Dr. Anderson recognized that the 
disease is autosomal recessive, however, after half a century in 1989 Lap-Chee Tsui 
in Canada discovered a gene called CFTR (CF transmembrane conductance regula-
tor), a mutation of which was responsible to cause CF [4]. Unfortunately, it was not 
the Holy Grail in the management of the CF as another 2000 variants of the gene 
mutation were found later on.
Even until the early part of the last century children affected with CF died of 
malnutrition. Discovery of pancreatic enzyme supplements and introduction of 
high-fat diet improved nutrition in CF children with many reaching to adulthood 
shifting the challenge to the pulmonary disease of CF. As more patients were diag-
nosed with the condition, a lot of organizations were founded in the western world 
to educate, support and treat CF. In 1965, the Royal Brompton hospital in London 
was the first in Europe, probably in the world to offer adult CF service [5]. Lack of 
knowledge and modern medicine in that era led to therapies like ‘mist tent’ where 
humidified air was delivered to liquefy mucus and ‘upside-down postural drainage’ 
to hasten expectorations. Over the decades, the discovery of various bugs affecting 
airways of CF patients and newer and more effective antibiotics to cull the bugs 
along with effective ways to deliver them including systematic inhalation saved 
many lives. The biggest breakthrough in the treatment of CF arrived at the begin-
ning of the current century when gene therapy directed at fixing the defect in the 
gene was successfully implemented [6, 7]. Early detection and management with a 
well-organized nutrition plan, improved airway clearance, targeted, combination 
and tailored antibiotic therapy along with ever-developing gene therapy should 
significantly improve survival in the CF patients.
2. Pathophysiology of cystic fibrosis
In the past, CF was called as ‘mucoviscidosis’ and the term quite aptly underlines 
the pathophysiology of the disease. The CF is an autosomal recessive disorder that 
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transpires due to mutation in the CFTR gene on chromosome 7 [8]. The CFTR is 
an anion channel on the surface of the epithelial cells that regulate cyclic AMP-
dependent and ATP energized secretion of chloride ions (Cl-) outside the cell and 
epithelial sodium channel (ENaC) regulated entry of Sodium ion (Na+) into the 
cell [9]. Simply put, the mutation in the gene leads to less secretion of chloride ion 
and inappropriate absorption of the sodium ion into the epithelial cells creating 
hyperosmolarity inside the cell and dehydration on its surface (Figure 1). F508del 
recognized by the absence of phenylalanine at position 508 in CFTR accounts for 
about two-thirds of mutations while the rest of the mutations measures less than 
5% individually [10]. Manifestations of CF involving various systems in the body 
are due to this genetic defect causing epithelial surface dehydration related vis-
cid mucus.
3. Clinical picture of cystic fibrosis
In the respiratory tract, abnormally dehydrated and thick mucus impedes 
normal mucociliary clearance creating a favorable environment for various organ-
isms infect and prosper with colonies. Due to persistent mucus, the airways are 
colonized with several pathogens which leads to the accumulation of inflammatory 
mediators and increases inflammation [11]. At early stages of life, the most common 
bacteria detected in the sputum are Staphylococcus aureus and Hemophilus influenzae, 
contrary to this Pseudomonas aeruginosa is the most prevalent bacteria during the 
second and third decade of life [12]. Pseudomonas aeruginosa, Burkholderia cepacia 
complex, and methicillin-resistant Staphylococcus aureus are known to be associated 
with CF morbidity and mortality [13]. Persistent productive cough, breathlessness, 
wheeze, to begin with, leads to chronic lung infections, recurrent sinusitis and 
decreased exercise tolerance. Vicious cycles of infection, inflammation and mucus 
build-up not only cause multiple pulmonary exacerbations but slowly damage 
respiratory airways culminating into bronchiectasis. In later stage complications 
like organized pneumonia, atelectasis, hemoptysis, pneumothorax, pulmonary 
hypertension, chronic hypoxic and hypercapnic respiratory failure and cor pulmo-
nale may occur [14, 15].
Abdominal manifestations of CF arise early in the course of the disease and 
have a severe impact on the quality of life of the patients. Dehydrated, concentrated 
pancreatic juices in CF patients cause a progressive obstruction and acute and 
chronic inflammation leading to parenchymal injury terminating into pancreatic 
insufficiency [16]. Clinical symptoms of pancreatic insufficiency include greasy 
Figure 1. 
Pathophysiology of cystic fibrosis.
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stools, flatulence, abdominal bloating, and poor weight gain. The CF liver disease 
is characterized by the hyper-viscous bile causing obstructive cholangitis initially 
leading to focal biliary fibrosis and subsequently to biliary multinodular cirrhosis 
and portal hypertension [17]. Gastrointestinal manifestations of CF occur due to 
pancreatic insufficiency, thickened intestinal secretions, undigested food remnants, 
poor motility, and fecal stasis with resultant impaction of mucofeculent material in 
the distal ileum and right colon presented as meconium ileus in the newborn and 
distal intestinal obstruction syndrome in the post-neonatal life. Manifestations of 
CF extend beyond respiratory and gastro-intestinal symptoms to practically every 
system of the body as shown in Figure 2. A peculiar manifestation of CF that defies 
systemic boundaries, however, is CF-related diabetes (CFRD) that involves charac-
teristics of both types of diabetes, that is, decreased secretion of insulin seen in type 
1 due to scarring of the pancreas and decreased sensitivity to insulin seen in type 2 
[18]. Incidence of CFRD increases with age and symptoms like unexplained weight 
loss, tiredness, increased thirst and micturition and sometimes decline in lung 
function can start in some patients in childhood itself. Microvascular complications 
like diabetic nephropathy, neuropathy and retinopathy are known to happen in 
untreated patients. Oral glucose tolerance test is a gold standard to detect the condi-
tion and should be performed at the age of 10 and yearly thereafter to diagnose and 
manage it at an early stage [19].
4. Diagnosis of cystic fibrosis
With the advent in diagnostic modalities, the CF is now diagnosed in newborns 
unlike a few decades ago when symptoms of CF and sometimes life-threatening 
CF complications prompted diagnostic procedures. However, even today false 
negative screening tests, migration, mild form of the disease and late presentation 
lets the condition undiagnosed until in the adulthood. Screening tests to clinch the 
diagnosis of CF at the earliest stage are offered at various levels. Carrier testing 
Figure 2. 
Clinical presentation of cystic fibrosis (credit wikimedia.org.png).
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with blood or buccal mucosa analysis for common mutations in the CFTR gene is 
indicated in people who wants to have children and have a relative affected with the 
CF. Antenatal testing involves chorionic biopsy or amniocentesis for similar genetic 
analysis and is offered to when partners are known carriers of the disease. Newborn 
screening involves testing immunoreactive trypsinogen (IRT) in heel prick blood 
which is increased in CF due to obstructed pancreatic ductus [20]. Raised IRT 
mandates sweat test which measures chloride concentration in the sweat that 
allows categorization of patients into CF, ‘CF unlikely’ and ‘intermediate’ as shown 
in Figure 3 prompting further evaluation by genetic testing in the intermediate 
category. In this, patients’ blood is checked for the number of copies of CFTR gene 
affected with most common CF mutations- the inheritance of 2 copies of mutated 
gene confirms CF, while undefined CFTR genotype or mutation of variable clinical 
consequence requires CFTR physiologic testing to establish the diagnosis of CF [21]. 
Nasal potential difference evaluating salt transport in the nasal epithelial cells and 
intestinal current measurement may further help elucidating the diagnosis of CF in 
this group of patients [22].
5. Management of cystic fibrosis
Management of CF-related complications varies and is dependent on 
disease severity and rate of progression and as a result, treatment is highly 
individualized.
As the progression of lung disease has significant prognostic implications for 
patients with CF, treatment of lung disease is one of the cornerstones of CF treat-
ment. Airway clearance is a key element of treatment and starts at birth or as soon 
as the patient is diagnosed. Airway clearance can be assisted by positive expiratory 
pressure devices and airway high-frequency chest wall oscillation techniques and 
should be performed daily (more frequently with advancing disease or during exac-
erbations) [23]. Airway clearance is assisted by treatments aimed at reducing the 
viscoelasticity of the mucous as thinner secretions are easier to expectorate. These 
involve nebulized treatment in the form of b-agonists, 3–6% hypertonic saline and 
dornase alpha as well as adequate levels of hydration [23, 24].
Figure 3. 
Diagnosis of cystic fibrosis.
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Preventing and controlling lung infections is central to the management of CF. 
Antibiotic regimes aim to prevent or treat exacerbations and to eradicate newly 
isolated pathogens. First isolation of gram-negative pathogens such as Pseudomonas 
aeruginosa should be prompt and attempt of eradication. Several eradications 
protocols including oral (typically ciprofloxacin) and inhaled antibiotics (typically 
tobramycin or colomycin) are available but details are beyond the scope of this 
chapter [25]. Prophylactic antibiotics aim to prevent or delay exacerbations, may be 
oral or inhaled and are used in conjunction with airway clearance techniques. They 
have been shown to reduce the frequency of exacerbations.
Pulmonary Exacerbations of CF include a combination of clinical symptoms, 
decline in lung function and oxygenation as well as rise of markers of inflamma-
tion. They are treated by a combination of antibiotic treatment, enhanced airway 
clearance and chest physiotherapy and supportive care as needed which may 
include oxygen supplementation or nutritional support. More severe exacerbations 
or exacerbations caused by more virulent and antibiotic-resistant pathogens will 
require intravenous antibiotics and a longer course of at least two weeks [24].
Haemoptysis and spontaneous pneumothorax are common complications of 
CF-related lung disease. Haemoptysis is often related to an infective exacerbation 
and treatment may be controlled with conservative measures such as treating the 
underlying infection and may require bronchial artery embolization or even lung 
resection. Repeated episodes of significant haemoptysis not controlled by emboliza-
tion may be an indication for lung transplantation [26].
Treatment of gastrointestinal manifestations of CF includes treatment of 
pancreatic insufficiency and management of CF-related diabetes as well as preven-
tion and treatment of intestinal blockage. Pancreatic insufficiency is treated with 
pancreatic enzyme replacement as well as nutritional support with high-calorie fat 
diet, vitamin supplementation and sodium chloride supplementation. Intestinal 
blockage prevention and treatment requires oral hydration, osmotic laxatives and 
hyperosmolar contrast enemas as needed [27, 28].
CF is a multisystem disease and therefore patients may also require treatment of 
other organs and systems such as complications from sinuses, urogenital complica-
tions as well as metabolic disorders such as reduced bone mineral density.
5.1 CFTR modulators – targeted treatment in CF disease
In recent years targeted therapy in the form of CFTR modulators has revolution-
ized the treatment of patients with CF. Oral, small molecules were developed that 
target the CFTR protein and have proven to be clinically successful in correcting 
the defect of the CFTR protein in vivo [29]. They are extremely efficacious and are 
transforming the care of patients living with CF - a chronic, progressive, multior-
gan disease- in an unprecedented way. A detailed description of CFTR modulators 
is beyond the scope of this chapter. The first CFTR modulator -ivacaftor- was suit-
able for a relatively small percentage of patients with CF. There are currently four 
single or combination therapies available (with more being investigated) and they 
have revolutionized the management of patients with CF. Numerous CFTR modula-
tors are currently being tested as well as gene engineering techniques aimed directly 
at the different mutations of the CF gene [30].
5.2 Lung transplantation in patients with CF
CF is a chronic progressive disease. Patients gradually develop structural changes 
in the lung parenchyma such as bronchiectasis. As the lung disease progresses the 
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frequency of exacerbation increases as well as the likelihood of complications such 
as pneumothoraces and haemoptysis both of which are associated with advanced 
disease. Patients eventually develop respiratory failure. In these cases, lung trans-
plantation presents a definitive treatment. Patients with reduced lung function 
(expressed as an FEV1 of <30% predicted), increasing frequency of exacerba-
tions and/or increase in symptom burden as well as patients with life-threatening 
haemoptysis not controlled by embolization or with persistent recurrent pneumo-
thorax should be considered for lung transplantation. Median survival after lung 
transplantation remains modest (7–8 years), however, it improves the quality of life 
and prognosis of patients with end-stage lung disease [26].
6. Conclusion
CF is a chronic, progressive, multiorgan disease caused by different mutations of 
the gene responsible for the CFTR protein. The involvement of lung disease is cen-
tral in the clinical manifestations of the disease and carries significant prognostic 
implications for patients with CF. Early diagnosis and aggressive management with 
airway clearance and antibiotic treatment of lung disease as well as vigorous man-
agement of extrapulmonary complications have significantly improved the quality 
of life and survival of patients with CF. Lung transplantation remains a definitive 
treatment in patients with end-stage lung disease. However, the management of CF 
disease has entered an exciting era with CFTR modulators targeting the defective 
CFTR protein and have revolutionized the management and prognosis of CF.
Future studies are looking at gene engineering to target CFTR gene mutations 
which will hopefully provide new therapeutic targets.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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